Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants

Frontiers in Pharmacology 12/2013; 4:161. DOI: 10.3389/fphar.2013.00161
Source: PubMed

ABSTRACT Newer antidepressants are needed for the many individuals with major depressive disorder (MDD) that do not respond adequately to treatment and because of a delay of weeks before the emergence of therapeutic effects. Recent evidence from clinical trials shows that the NMDA antagonist ketamine is a revolutionary novel antidepressant because it acts rapidly and is effective for treatment-resistant patients. A single infusion of ketamine alleviates depressive symptoms in treatment-resistant depressed patients within hours and these effects may be sustained for up to 2 weeks. Although the discovery of ketamine's effects has reshaped drug discovery for antidepressants, the psychotomimetic properties of this compound limit the use of this therapy to the most severely ill patients. In order to develop additional antidepressants like ketamine, adequate preclinical behavioral screening paradigms for fast-acting antidepressants need to be established and used to identify the underlying neural mechanisms. This review examines the preclinical literature attempting to model the antidepressant-like effects of ketamine. Acute administration of ketamine has produced effects in behavioral screens for antidepressants like the forced swim test, novelty suppression of feeding and in rodent models for depression. Protracted behavioral effects of ketamine have been reported to appear after a single treatment that last for days. This temporal pattern is similar to its clinical effects and may serve as a new animal paradigm for rapid antidepressant effects in humans. In addition, protracted changes in molecules mediating synaptic plasticity have been implicated in mediating the antidepressant-like behavioral effects of ketamine. Current preclinical studies are examining compounds with more specific pharmacological effects at glutamate receptors and synapses in order to develop additional rapidly acting antidepressants without the hallucinogenic side effects or abuse potential of ketamine.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Antidepressants are known to positively influence several factors in patients with depressive disorders, resulting in increased neurogenesis and subsequent relief of depressive disorders. To study the effects of venlafaxine during neural differentiation at the cellular level, we looked at its effect on protein expression and regulation mechanisms during neural differentiation. After exposing NCCIT cell-derived EBs to venlafaxine during differentiation (1 day and 7 days), changes in protein expression were analyzed by 2-DE and MALDI-TOF MS analysis. Gene levels of proteins regulated by venlafaxine were analyzed by real-time RT-PCR. Treatment with venlafaxine decreased expression of prolyl 4-hydroxylase (P4HB), ubiquitin-conjugating enzyme E2K (HIP2) and plastin 3 (T-plastin), and up-regulated expression of growth factor beta-3 (TGF-β3), dihydropyrimidinase-like 3 (DPYSL3), and pyruvate kinase (PKM) after differentiation for 1 and 7 days. In cells exposed to venlafaxine, the mRNA expression patterns of HIP2 and PKM, which function as negative and positive regulators of differentiation and neuronal survival, respectively, were consistent with the observed changes in protein expression. Our findings may contribute to improve understanding of molecular mechanism of venlafaxine.
    Psychiatry investigation 01/2015; 12(1):81-91. DOI:10.4306/pi.2015.12.1.81 · 1.15 Impact Factor
  • Molecular Psychiatry 11/2014; 20(1):48-55. DOI:10.1038/mp.2014.138 · 15.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Previous studies demonstrated that systemic administration of lidocaine could induce central nervous toxicities, including behavioral convulsion as well as cognitive and cellular injury. Ketamine, a general anesthetic, is commonly used as an adjuvant in regional anesthesia with combination of lidocaine. The present was designed to investigate the effects of ketamine in central nervous toxicities of lidocaine. Ketamine (1.2 mg/kg, i.v.) was intravenously injected before and/or after administration of lidocaine in rats. After injection of lidocaine, convulsive behaviors of rats were scored according to the modified Racine scale. Cognitive functions and pathology of hippocampus CA3 pyramid neurons of these rats were evaluated on the one, three, five, and seven days after lidocaine induced convulsion. Both pre- and/or post-administration of ketamine (1.2 mg/kg) could significantly improve lidocaine induced convulsive behaviors of rats (P < 0.01). One, three, five, and seven days after lidocaine induced convulsion, cognitive function and pathology of hippocampus CA3 pyramid neurons of these rats were significantly impaired. In addition, cognitive functions and pathology of neurons of the rats that received ketamine (both pre- and/or post-) were further impaired, compared to the rats without ketamine. We conclude that both pre- and/or post-administration of ketamine could improve lidocaine induced convulsive behaviors. However, cognitive functions and pathology of neurons of these rats are further impaired, compared to the rats without ketamine. This result indicates that ketamine combined with lidocaine might be risky in regional anesthesia.
    International Journal of Clinical and Experimental Medicine 01/2014; 7(12):5104-10. · 1.42 Impact Factor

Full-text (3 Sources)

Available from
May 16, 2014

Caroline Ann Browne